Who
Charles A. Bancroft
Director
Company insider
Files Form 4 as: Director, Kodiak Sciences; EVP, Head of Integration, Bristol-Myers Squibb; Director, Colgate-Palmolive.
In numbers
- Trades disclosed
- 347
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $11.1M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 1 Mar 2010
- Last trade
- 30 Jun 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 2 Jul 2026 | KOD Kodiak Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,731 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KOD Kodiak Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,731 at $0.00 | filing |
| 30 Jun 2025filed 2 Jul 2025 | KOD Kodiak Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 28 Jun 2024filed 1 Jul 2024 | KOD Kodiak Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 30 Jun 2023filed 3 Jul 2023 | KOD Kodiak Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 30 Jun 2022filed 5 Jul 2022 | KOD Kodiak Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 30 Jun 2021filed 2 Jul 2021 | KOD Kodiak Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,368 at $0.00 | filing |
| 30 Jun 2020filed 2 Jul 2020 | KOD Kodiak Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,104 at $0.00 | filing |
| 2 Apr 2020filed 6 Apr 2020 | KOD Kodiak Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,293 at $0.00 | filing |
| 10 Mar 2020filed 12 Mar 2020 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,174 at $0.00 | filing |
| 10 Mar 2020filed 12 Mar 2020 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —7,324 at $0.00 | filing |
| 10 Mar 2020filed 12 Mar 2020 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,207 at $0.00 | filing |
| 10 Mar 2020filed 12 Mar 2020 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,219 at $0.00 | filing |
| 10 Mar 2020filed 12 Mar 2020 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —43,944 at $0.00 | filing |
| 10 Mar 2020filed 12 Mar 2020 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code G | —300,000 at $0.00 | filing |
| 10 Mar 2020filed 12 Mar 2020 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code G | —300,000 at $0.00 | filing |
| 10 Mar 2020filed 12 Mar 2020 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —6,174 at $0.00 | filing |
| 10 Mar 2020filed 12 Mar 2020 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code J | —100 at $0.00 | filing |
| 10 Mar 2020filed 12 Mar 2020 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code F | $149K2,577 at $57.93 | filing |
| 10 Mar 2020filed 12 Mar 2020 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —7,324 at $0.00 | filing |
News
Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?BMY · aol.com · 22 Oct 2026Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 VolatilityBMY · fool.com · 22 Oct 2026AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?BMY · fool.com · 21 Oct 2026
0 headlines in the last 90 days name Charles A. Bancroft; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.